Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTFORCE: Adaptive Chemoradiation vs Standard Chemoradiation/Cetuximab in SCCHN
2012-000437-39Phase 2Active
- Sponsor
- Netherlands Cancer Institute
- Start
- Mar 2012
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of cisplatin and cetuximab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Locoregional recurrence-free survival at 2 years. Started Mar 2012; status: active.
02
Drugs
cisplatincetuximab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2012-000437-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000437-39.